Trial
NCT03099161
Study of Preladenant (MK-3814) Alone and With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3814A-062)
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Merck Sharp & Dohme LLC
Collaborators
—
Condition
Neoplasm
Intervention
preladenant
Why stopped
The data did not support study endpoints
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-06-05